Momenta Pharma (MNTA) March option implied volatility at 138 into Update
More News related to MNTA
- Momenta Pharmaceuticals (MNTA) March put volatility elevated at 131
- Momenta Pharma (MNTA) Posts Q3 Loss of $0.38, Tops by 2c
- Momenta Pharmaceuticals (MNTA) Tops Q3 EPS by 2c; Revs Light
- Momenta Pharmaceuticals Reports Financial Results for the Third Quarter of 2009
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
More News related to FDA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
Momenta Pharma (Nasdaq: MNTA) : MNTA is expected to provide an update on M-Enoxaparin ANDA, a generic form of SNY's Lovenox, ($1.5 billion in sales in 2005) a treatment to fight leg blood clots in early 2007. MNTA March option implied volatility of 138 is above its 6-month average of 90 according to Track Data, suggesting larger price risks. Paul Foster
Related Categories
FDAOptions
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
